Baxter International is a healthcare company that focuses on developing and providing a wide range of medical products and services to enhance patient care
The company specializes in creating innovative therapies and solutions for various health conditions, including renal and hospital care. With a strong emphasis on sustainability and improving patient outcomes, Baxter manufactures essential medical devices, pharmaceuticals, and biotechnology products that support the treatment of chronic diseases and acute medical conditions. Their commitment to research and development drives advancements in healthcare technology, helping to meet the needs of healthcare professionals and patients worldwide.
Baxter International Inc. (NYSEBAX), a global medtech leader, today announced that José (Joe) E. Almeida, chair, president and chief executive officer (CEO), will retire from his executive roles with the company, effective immediately. He will serve in an advisory capacity through Oct. 31, 2025.
Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and care teams with more flexible, collaborative and accessible care options
Baxter International Inc. (NYSEBAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2024 financial results on Thursday, February 13, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I2823858 to pre-register for the call and receive the call information.
This afternoon felt like either a fund blew up or the margin clerks were taking a bunch of dumb over-leveraged money out to the woodshed to put them out of their misery.
Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. José (Joe) E. Almeida, Baxter's chair, president and chief executive officer, is scheduled to present at 10:30 a.m. Pacific Time.
Baxter International Inc. (NYSEBAX), a global leader in injectables, anesthesia and drug compounding, today announced five new injectable pharmaceutical product launches in the U.S., joining the previous five launches announced in April of this year and marking a total of 10 U.S. injectable product launches in 2024.
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Baxter International (BAX) cut its dividend because of the upcoming sale of the Kidney Care business, high debt and leverage, lower earnings per share, and free cash flow.
Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the 7th Annual Evercore HealthCONx Conference on Thursday, December 5, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 9:10 a.m. Eastern Time.
Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 11:00 a.m. Greenwich Mean Time.
Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 8:35 a.m. Eastern Time.
Baxter International Inc. (NYSEBAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share of common stock.
Baxter International Inc. (NYSEBAX), a global medtech leader, will present at the UBS Global Healthcare Conference on Wednesday, November 13, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:15 p.m. Pacific Time.
The U.S. faces a critical shortage of IV fluids due to Hurricane Helene's damage to Baxter's North Carolina plant, forcing hospitals to delay surgeries. Federal efforts to rebuild and import supplies aim to ease the crisis by year-end.
Baxter International Inc. (NYSEBAX), a global medtech leader, will host a conference call to discuss its third-quarter 2024 financial results on Friday, November 8, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/attendee/391655054 to pre-register for the call and receive the call information.
Baxter International resumes IV fluid shipments from international sites after Hurricane Helene disrupted production at its North Carolina plant, which supplies 60% of U.S. IV fluids. FDA approves temporary imports to ease the shortage.
U.S. Senator Amy Klobuchar has called on HHS Secretary Xavier Becerra to address the national IV solution shortage following the closure of Baxter's facility due to Hurricane Helene, which compromises patient care and poses risks of price gouging.
